The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Compass Therapeutics Inc. shares valued at $56,000 were purchased by Schuetz Thomas J. on Jun 21. At $2.80 per share, Schuetz Thomas J. acquired 20,000 shares. The insider’s holdings grew to 5,331,873 shares worth approximately $14.82 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Schuetz Thomas J. purchased 20,000 shares, netting a total of over 46,800 in proceeds. Following the buying of shares at $2.34 each, the insider now holds 5,311,873 shares.
Before that, Schuetz Thomas J. had added 30,000 shares to its account. In a trade valued at $68,700, the CHIEF EXECUTIVE OFFICER bought Compass Therapeutics Inc. shares for $2.29 each. Upon closing the transaction, the insider’s holdings increased to 30,000 shares, worth approximately $14.71 million.
As published in their initiating research note from Raymond James on April 08, 2022, The Procter & Gamble Company [PG] has been an Outperform and the price target has been revised to $175. This represents a 20.86% premium over Wednesday’s closing price. Analysts at JP Morgan downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in late March. As of March 22, 2022, Truist has increased its “Hold” rating to a “Buy” for PG. This represents a 76.83% premium over Wednesday’s closing price. Analysts at Ladenburg Thalmann started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of January 19, 2022, B. Riley Securities has initiated its “Buy” rating for CMPX. Earlier on December 22, 2021, Raymond James initiated its rating. Their recommendation was “an Outperform” for CMPX stock.
Analyzing CMPX’s Price Performance
On Wednesday, Compass Therapeutics Inc. [NASDAQ: CMPX] plunged -4.79% to $2.78. The stock’s lowest price that day was $2.66, but it reached a high of $3.005 in the same session. During the last five days, there has been a surge of approximately 30.52%. Over the course of the year, Compass Therapeutics Inc. shares have dropped approximately -12.30%. Shares of the company reached a 52-week high of $3.50 on 01/06/22 and a 52-week low of $1.25 on 03/29/22. A 50-day SMA is recorded $2.17, while a 200-day SMA reached $2.61. Nevertheless, trading volume fell to 0.13 million shares from 0.11 million shares the previous day.
Support And Resistance Levels for Compass Therapeutics Inc. (CMPX)
According to the 24-hour chart, there is a support level at 2.63, which, if violated, would cause prices to drop to 2.47. In the upper region, resistance lies at 2.97. The next price resistance is at 3.16. RSI (Relative Strength Index) is 56.91 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.13, which suggests the price will decrease in the coming days. Percent R is at 32.56%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Compass Therapeutics Inc. (CMPX)?
According to Rock Springs Capital Management L filings, the company currently owns 5,328,088 shares, which is about 5.26% of the total CMPX shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 5328088.0 shares. With the completion of the sale, Consonance Capital Management LP’s stake is now worth $10,675,000. Janus Henderson Investors US LLC acquire a 116.85% interest valued at $9.74 million while CHI Advisors LLC sold a -193,980 stake. A total of 0 shares of Compass Therapeutics Inc. were sold by Fidelity Management & Research Co during the quarter, and 877,000 were bought by Adage Capital Management LP. In its current portfolio, Avidity Partners Management LP holds 2,000,000 shares valued at $6.1 million.
In terms of Compass Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $9.29 in the next 12 months, up nearly 242.47% from the previous closing price of $2.92. Analysts anticipate Compass Therapeutics Inc. stock to reach $12.00 by 2022, with the lowest price target being $5.00. In spite of this, 7 analysts ranked Compass Therapeutics Inc. stock as a Buy at the end of 2022. On December 20, 2021, SVB Leerink assigned a price target of “an Outperform” to the stock and initiated coverage with a $12.